Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Ann Leen Biography and Net Worth

Insider of AlloVir

Dr. Ann Leen co-founded and serves as Chief Scientific Officer of AlloVir. For more than 20 years, Dr. Leen has led innovative discovery and translational research focused on developing novel T cell-based therapies. Her research has enabled multiple cell therapy programs to move from bench to bedside. She is currently the principal investigator (PI) on 5 investigator-initiated Investigational New Drug (IND) studies and over the past 10 years has served as PI on more than 10 clinical trials using “first in man” cell therapies for patients.

In addition to her role at AlloVir, Dr. Leen continues to serve as Professor in the Department Pediatrics at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, where she has held various faculty positions since 2005. She is senior or co-author on more than 90 publications and a named inventor on 14 published patents.

Ann received her B.S. in Biochemistry at the University of College Cork in Cork, Ireland and her Ph.D. in Immunology at the CRC Institute for Cancer Studies in Birmingham, UK.

What is Ann M. Leen's net worth?: The estimated net worth of Ann M. Leen is at least $21,193.20 as of May 10th, 2021. Dr. Leen owns 28,000 shares of AlloVir stock worth more than $21,193 as of April 17th. This net worth evaluation does not reflect any other assets that Dr. Leen may own. Learn More about Ann M. Leen's net worth.
How old is Ann M. Leen?: Dr. Leen is currently 46 years old. There are 7 older executives and no younger executives at AlloVir. The oldest executive at AlloVir is Mr. Vikas Sinha C.A., CPA, M.B.A., President, CFO & Director, who is 61 years old. Learn More on Ann M. Leen's age.
How do I contact Ann M. Leen?: The corporate mailing address for Dr. Leen and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Ann M. Leen's contact information.
Has Ann M. Leen been buying or selling shares of AlloVir?: Ann M. Leen has not been actively trading shares of AlloVir in the last ninety days. Most recently, Ann M. Leen sold 6,122 shares of the business's stock in a transaction on Monday, November 15th. The shares were sold at an average price of $21.92, for a transaction totalling $134,194.24. Learn More on Ann M. Leen's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, AlloVir insiders bought shares 1 times. They purchased a total of 2,930,870 shares worth more than $10,990,762.50. In the last year, insiders at the sold shares 40 times. They sold a total of 190,558 shares worth more than $312,701.31. The most recent insider tranaction occured on April, 2nd when General Counsel Edward Miller sold 368 shares worth more than $283.36. Insiders at AlloVir own 40.0% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 4/2/2024.

Ann M. Leen Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2021	Sell	6,122	$21.92	$134,194.24
11/12/2021	Sell	14,766	$22.30	$329,281.80
5/10/2021	Sell	150,000	$22.75	$3,412,500.00	28,000
3/16/2021	Sell	3,025	$30.00	$90,750.00	28,000
2/18/2021	Sell	2,700	$40.81	$110,187.00	28,000
2/16/2021	Sell	3,050	$41.88	$127,734.00	28,000

Ann M. Leen Buying and Selling Activity at AlloVir

AlloVir Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $0.76

$0.72

$0.77

50 Day Range

MA: $0.73

$0.67

$0.80

2 Week Range

Now: $0.76

$0.62

$6.12

Volume

572,247 shs

Average Volume

1,233,994 shs

Market Capitalization

$86.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad